Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rapid emergence of antibiotic resistance during standard therapy

21.11.2019

Kiel research team investigates how the pathogen Pseudomonas aeruginosa becomes resistant to antibiotics during treatment of cystic fibrosis patients

Antibiotic-resistant pathogens pose one of the greatest threats to public health worldwide. In the near future, harmless bacterial infections may no longer be treatable and may again become the most common non-natural cause of death.


First author Dr Leif Tüffers investigated the evolution of resistance in the pathogen Pseudomonas aeruginosa during antibiotic treatment in a cohort of cystic fibrosis patients.

© Christian Urban, Kiel University


The isolates of the pathogen obtained from the bronchial secretions of the patients are preserved at -80 °Celsius for further examination.

© Christian Urban, Kiel University

At the same time, the available repertoire of antibacterial agents is becoming increasingly smaller as resistance rates rise. The basic mechanisms of resistance evolution, i.e. the adaptation of a disease germ to the mode of action of a drug, have been well researched experimentally. How such loss of drug susceptibility develops in individual patients in the course of standard antibiotic therapy has not yet been studied.

A research team from the department of Evolutionary Ecology and Genetics at Kiel University has now investigated the evolution of resistance in the pathogen Pseudomonas aeruginosa during antibiotic treatment in a cohort of cystic fibrosis patients as an example. For the first time, they researched to what extent resistance evolves during a single course of antibiotic therapy.

The researchers now found that resistance rapidly emerged in about one third of the patients. These findings were obtained within the Leibniz ScienceCampus "EvoLUNG" and the Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) and were recently published in the Journal of Antimicrobial Chemotherapy.

Cystic fibrosis lung infection as an example

In the study, the research team focused on a small cohort of cystic fibrosis patients. The disease, which is uncurable to date, is caused by impaired cellular water transport and leads to viscous body secretions and associated dysfunction of numerous organs. It affects the respiratory tract and lungs in particular. Frequent infections in adult patients are mainly caused by Pseudomonas. As a result, they have to be treated with antibiotics frequently or even permanently.

In order to assess whether resistance evolves in the course of a single standard treatment with two or more antibiotics, the scientists examined the bronchial secretions of the patients daily and isolated Pseudomonas bacteria. This enabled them to investigate how the bacteria adapted to therapy over a period of 14 days. "In every third patient the pathogen adapted surprisingly quickly to the administered drugs and antibiotic resistance evolved within one to three days," summarised Dr Leif Tüffers, a researcher in the Department of Evolutionary Ecology and Genetics. "The rapid evolution of resistance mainly affected newly administered antibiotics from the betalactam drug class," continued Tüffers.

Findings match evolutionary experiments

These findings were obtained in real time on patients during clinical routine therapy for the first time. They generally correspond well with experimental observations from previous laboratory experiments with the Pseudomonas pathogen. Although resistances evolve faster in the laboratory, sometimes within a few hours, the bacteria in the patient's body grow much more slowly. To date, it is not entirely clear how exactly bacteria in the patients achieve such rapid evolution of resistance to the betalactam antibiotics, including penicillin. "It is possible that this rapid adaptation to the drug occurs as a result of spontaneous, new mutations in resistance genes," said Tüffers.

In current research within the Cluster of Excellence PMI, the scientists now investigate the clinical applicability of evolution-based treatment strategies, which proved successful under laboratory conditions in the past. "The processes of resistance evolution are often comparable, regardless of whether it is a laboratory experiment with a specific single bacterium or the treatment of a bacterial infection in patients," said Professor Hinrich Schulenburg, head of the Department of Evolutionary Ecology and Genetics at Kiel University. "We therefore want to investigate in future studies to what extent, for example, the principle of collateral sensitivity, in which the formation of resistance to one antibiotic increases sensitivity to a second drug, can be used to treat lung infections," continued Schulenburg.

Pictures are available for download:

https://www.uni-kiel.de/de/pressemitteilungen/2019/362-tueffers-jac-author.JPG
Caption: First author Dr Leif Tüffers investigated the evolution of resistance in the pathogen Pseudomonas aeruginosa during antibiotic treatment in a cohort of cystic fibrosis patients. © Christian Urban, Kiel University

https://www.uni-kiel.de/de/pressemitteilungen/2019/362-tueffers-jac-samples.JPG
Caption: The isolates of the pathogen obtained from the bronchial secretions of the patients are preserved at -80 °Celsius for further examination. © Christian Urban, Kiel University

https://www.uni-kiel.de/de/pressemitteilungen/2019/362-tueffers-jac-vortex.jpg
Caption: Using a so-called vortexer, the bacterial isolates are prepared for the analysis of their genetic information. © Christian Urban, Kiel University

More information:

Department of Evolutionary Ecology and Genetics,
Zoological Institute, Kiel University:
http://www.uni-kiel.de/zoologie/evoecogen

Leibniz ScienceCampus for Evolutionary Medicine of the Lung:
http://evolung.fz-borstel.de

Wissenschaftliche Ansprechpartner:

Prof. Hinrich Schulenburg
Head of the Department of Evolutionary Ecology and Genetics,
Kiel University
Tel.: +49 (0) 431-880-4141
E-mail: hschulenburg@zoologie.uni-kiel.de

Dr Leif Tüffers
Department of Evolutionary Ecology and Genetics,
Zoological Institute, Kiel University
Tel.: +49 (0) 431-880-4145
E-mail: ltueffers@zoologie.uni-kiel.de

Originalpublikation:

Original publications:
Leif Tueffers, Camilo Barbosa, Ingrid Bobis, Sabine Schubert, Marc Höppner, Malte Rühlemann, Andre Franke, Philip Rosenstiel, Anette Friedrichs, Annegret Krenz-Weinreich, Helmut Fickenscher, Burkhard Bewig, Stefan Schreiber and Hinrich Schulenburg (2019): Pseudomonas aeruginosa populations in the cystic fibrosis lung lose susceptibility to newly applied beta-lactams within 3 days.
Journal of Antimicrobial Chemotherapy
https://doi.org/10.1093/jac/dkz297

Weitere Informationen:

http://www.uni-kiel.de/zoologie/evoecogen
http://evolung.fz-borstel.de

Dr. Boris Pawlowski | idw - Informationsdienst Wissenschaft

More articles from Health and Medicine:

nachricht Novel communication between intestinal microbes and developing immune cells in the thymus
24.01.2020 | Massachusetts General Hospital

nachricht Preventing metastasis by stopping cancer cells from making fat
23.01.2020 | Université catholique de Louvain

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Integrate Micro Chips for electronic Skin

Researchers from Dresden and Osaka present the first fully integrated flexible electronics made of magnetic sensors and organic circuits which opens the path towards the development of electronic skin.

Human skin is a fascinating and multifunctional organ with unique properties originating from its flexible and compliant nature. It allows for interfacing with...

Im Focus: Dresden researchers discover resistance mechanism in aggressive cancer

Protease blocks guardian function against uncontrolled cell division

Researchers of the Carl Gustav Carus University Hospital Dresden at the National Center for Tumor Diseases Dresden (NCT/UCC), together with an international...

Im Focus: New roles found for Huntington's disease protein

Crucial role in synapse formation could be new avenue toward treatment

A Duke University research team has identified a new function of a gene called huntingtin, a mutation of which underlies the progressive neurodegenerative...

Im Focus: A new look at 'strange metals'

For years, a new synthesis method has been developed at TU Wien (Vienna) to unlock the secrets of "strange metals". Now a breakthrough has been achieved. The results have been published in "Science".

Superconductors allow electrical current to flow without any resistance - but only below a certain critical temperature. Many materials have to be cooled down...

Im Focus: Programmable nests for cells

KIT researchers develop novel composites of DNA, silica particles, and carbon nanotubes -- Properties can be tailored to various applications

Using DNA, smallest silica particles, and carbon nanotubes, researchers of Karlsruhe Institute of Technology (KIT) developed novel programmable materials....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

 
Latest News

Brain-cell helpers powered by norepinephrine during fear-memory formation

24.01.2020 | Life Sciences

Engineered capillaries model traffic in tiny blood vessels

24.01.2020 | Life Sciences

Predictive touch response mechanism is a step toward a tactile internet

24.01.2020 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>